QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jim-cramer-hold-on-to-builders-firstsource-heres-the-problem-with-viking-therapeutics

Jim Cramer discusses Serve Robotics, Builders FirstSource, Vertex Pharmaceuticals and Viking Therapeutics on CNBC.

 nsa-code-breaker-jim-simons-hedge-fund-renaissance-technologies--ozempic-wegovy-maker-novo-nordisk-along-with-nvidia-palantir-among-top-holdings

Renaissance Technologies, the hedge fund founded by legendary mathematician and former NSA code breaker Jim Simons, recently di...

 reported-earlier-vertex-secures-nhs-england-reimbursement-for-groundbreaking-casgevy-therapy-for-transfusion-dependent-beta-thalassemia

- Eligible transfusion-dependent beta thalassemia (TDT) patients in England will be able to access the therapy from today - ...

 hc-wainwright--co-maintains-buy-on-vertex-pharmaceuticals-raises-price-target-to-600

HC Wainwright & Co. analyst Andrew Fein maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price t...

 oppenheimer-maintains-outperform-on-vertex-pharmaceuticals-raises-price-target-to-550

Oppenheimer analyst Hartaj Singh maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperform and raises the price targe...

 jp-morgan-maintains-overweight-on-vertex-pharmaceuticals-raises-price-target-to-510

JP Morgan analyst Jessica Fye maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target f...

 truist-securities-reiterates-buy-on-vertex-pharmaceuticals-raises-price-target-to-550

Truist Securities analyst Joon Lee reiterates Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target fr...

 barclays-downgrades-vertex-pharmaceuticals-to-equal-weight-raises-price-target-to-509

Barclays analyst Gena Wang downgrades Vertex Pharmaceuticals (NASDAQ:VRTX) from Overweight to Equal-Weight and raises the pr...

 guggenheim-maintains-buy-on-vertex-pharmaceuticals-raises-price-target-to-558

Guggenheim analyst Debjit Chattopadhyay maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price targe...

 magnificent-7-lose-over-300b-as-volatility-index-surges-traders-question-feds-timing-whats-driving-markets-friday

Wall Street is experiencing a sharp decline on the last trading day of the week, with all indices in the red at noon in New Yor...

 vertex-pharmaceuticals-lifts-annual-guidance-positive-growth-for-its-cystic-fibrosis-franchise-and-pain-management-pipeline

Vertex Pharmaceuticals reported Q2 revenues of $2.65B, near the $2.66B estimate, with an adjusted EPS loss of $(12.83), missing...

 cantor-fitzgerald-reiterates-overweight-on-vertex-pharmaceuticals-maintains-480-price-target

Cantor Fitzgerald analyst Olivia Brayer reiterates Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and maintains $480...

 piper-sandler-maintains-overweight-on-vertex-pharmaceuticals-raises-price-target-to-535

Piper Sandler analyst Christopher Raymond maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the pr...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION